Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 + Standard IST in Severe Aplastic Anemia
NCT06613880Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Response Rate at 27 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06613880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613880.